We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,444 hedge funds and large institutions have $99.1B invested in Bristol-Myers Squibb in 2021 Q4 according to their latest regulatory filings, with 328 funds opening new positions, 862 increasing their positions, 1,008 reducing their positions, and 137 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more first-time investments, than exits

New positions opened: 328 | Existing positions closed: 137

26% more call options, than puts

Call options by funds: $1.95B | Put options by funds: $1.55B

7% more funds holding

Funds holding: 2,2922,444 (+152)

3% more capital invested

Capital invested by funds: $96.2B → $99.1B (+$2.9B)

0% more funds holding in top 10

Funds holding in top 10: 6464 (0)

1.18% less ownership

Funds ownership: 73.4%72.22% (-1.2%)

14% less repeat investments, than reductions

Existing positions increased: 862 | Existing positions reduced: 1,008

Holders
2,444
Holders Change
+152
Holders Change %
+6.63%
% of All Funds
37.61%
Holding in Top 10
64
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.98%
New
328
Increased
862
Reduced
1,008
Closed
137
Calls
$1.95B
Puts
$1.55B
Net Calls
+$401M
Net Calls Change
+$135M

BMY Hedge Fund Activity: Q4 2021 in Review

2,444 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2021, worth a combined $99.1B — up 3% from $96.2B a quarter earlier.

Buyers outnumbered sellers: 328 funds opened new BMY positions and 137 closed out — a net gain of 191 holders — while 862 added to existing stakes and 1,008 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $362M. The largest seller was Berkshire Hathaway, cutting an estimated $988M.

  • 2,444 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2021, up from 2,292 in Q3 2021.
  • Funds reported $99.1B of Bristol-Myers Squibb stock for Q4 2021, up 3% quarter-over-quarter.
  • 328 funds opened new Bristol-Myers Squibb positions in Q4 2021 and 137 closed out, a net change of +191 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2021 was JP Morgan Chase, an estimated $362M added.
  • The largest Bristol-Myers Squibb seller in Q4 2021 was Berkshire Hathaway, an estimated $988M sold.

Based on aggregated 13F filings for Q4 2021.